Health experts are wondering if the measles outbreak is a lot larger than it seems
If that is the case, authorities would need to act quickly and decisively to halt its continuing spread, which could potentially prove fatal in additional largely unvaccinated communities.
So far, 223 cases have been identified across the Lone Star State since late January, and 29 patients have been hospitalized. Last month, the Texas Department of State Health Services warned that an infected individual may have exposed people — potentially hundreds of thousands — while traveling between San Marcos and San Antonio before they knew they were infected.
But it's the deaths, in particular, that are concerning. The first fatality was reported in an unvaccinated child who had no underlying conditions and lived in the outbreak area. A second death was reported in New Mexico's nearby Lea County, also an unvaccinated patient. Their official cause of death remains under investigation, but the state's Department of Health confirmed the presence of the measles virus. New Mexico has reported 33 cases.
With this many deaths, experts wonder if there should be more cases. In the U.S., death from complications of the virus occur in one to three of every 1,000 cases, according to the University of Chicago Medical Center. Infection can also lead to brain inflammation that can result in permanent damage.
'These two individuals could just be incredibly unlucky,' epidemiologist Katelyn Jetelina told STAT News on Wednesday. 'It's just surprising, particularly given how few deaths we've had over the past 10 years.'
'My gut tells me there are cases that are unreported — you don't have to come in and get tested for measles,' Katherine Wells, the director of public health in Lubbock, told the outlet. 'It's going to be a long process to get everything measles-free again in this area, but I can't tell you if that's 500 cases or a thousand.'
Texas says that, due to the nature of the measles virus, additional cases are likely to occur in the outbreak area and surrounding communities.
Several obstacles are getting in the way of capturing the full scale of the country's largest outbreak in six years. Many of those in areas that could have exposures may not be cooperative or report infection.
It's also possible that people don't know they are infected, especially in breakthrough cases. According to the Mayo Clinic, measles symptoms generally appear 10 to 14 days after exposure to the virus. Breakthrough infections in vaccinated people are linked to milder disease. Those cases are rare, but people near the outbreak are more susceptible.
However, what is known is that measles is preventable through vaccines, and the risk of infection is present, thanks to dipping vaccination rates. Childhood vaccination rates have declined nationwide since the pandemic, and San Antonio-area schools are reportedly seeing more students opt out of vaccines, according to the San Antonio Express-News.
It's not unexpected to see one or two cases in communities with high vaccine coverage. But Johns Hopkins University's Dr. Bill Moss cautions that another outbreak could occur if someone with measles goes to another community with a large population of unvaccinated individuals, which could leach into other areas.
'If your population around you has a measles vaccination rate of 95 percent or greater, that keeps the risk of an outbreak pretty low because even if one person had it, everybody else around that person is going to be vaccinated,' Dr. Erica Kaufman West, director of infectious diseases in the department of science, medicine and public health at the American Medical Association, said. 'Once it drops under 95 percent though, that's where you start to see these pockets of outbreaks.'
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


CBS News
21 hours ago
- CBS News
Measles case confirmed in Passaic County, New Jersey, health officials say
A case of measles has been confirmed in Passaic County, New Jersey, health officials announced Saturday. According to the state Department of Health, the patient recently traveled internationally, and this case is not related to measles cases in Hudson and Ocean counties that were reported in July. Health officials say the patient visited the Chilton Medical Center in Pompton Plains while contagious. Anyone who was in the emergency department between 7 p.m. on July 31 and 3:30 a.m. on Aug. 1 or the main hospital's fifth floor Intensive Care Unit between 1:30 a.m. and 12:30 p.m. on Aug. 1 may have been exposed to measles. Anyone who was exposed at those times could develop symptoms as late as Aug. 24, if infected. This is the sixth case of measles in New Jersey so far this year. Measles is spread when an infected person coughs or sneezes and can remain in the air for up to two hours. It can also be spread through an infected person's mucus or saliva. According to health officials, measles symptoms include high fever, cough, runny nose, watery red eyes, and a rash that appears as flat red spots on the face and all over the body. Anyone who suspects they have or were exposed to measles should call their local health department or health care provider to make special arrangements for evaluation. Potential patients are urged to call ahead before arriving at a medical office or emergency department due to the risk of infecting other visitors and medical staff. Those who have not received both doses of the MMR vaccine or had measles in the past are most at risk of becoming infected. All New Jersey residents are encouraged to stay up to date on vaccinations, and anyone travelling internationally should be fully vaccinated before leaving the country, the health department says. Data released by the Centers for Disease Control and Prevention in July shows 2025 is the worst year for measles in the United States since 1992. There have been 14 measles cases in New York so far this year, according to the latest state health department data. That includes seven cases in New York City, four cases in Orange County, one in Putnam County, one in Suffolk County and one in Ontario County. There have not been any cases of measles in Connecticut so far this year.


Forbes
2 days ago
- Forbes
A Regulated Trip: What New Mexico's Psilocybin Law Means For Work
Magic mushrooms are now medicine in New Mexico. And that shift could have ripple effects in the workplace. This spring, Governor Michelle Lujan Grisham signed Senate Bill 219, the Medical Psilocybin Act, into law, making New Mexico the third state to legalize psilocybin for medical use. Unlike Oregon and Colorado, which adopted their psilocybin programs through ballot initiatives, New Mexico enacted its law through the legislative process. That distinction is more than procedural. It reflects an institutional shift toward integrating psychedelic therapy into the framework of state-managed healthcare. The law took effect on June 20, 2025, and requires full program implementation by December 31, 2027. With that, New Mexico becomes the first state to create a clinician-administered psilocybin program governed by medical oversight, not consumer access. As psilocybin therapy enters a regulated medical model, employers must now examine how psilocybin intersects with workplace safety, disability accommodation, and drug policy enforcement. Psilocybin's Reintroduction as Medicine Psilocybin is a naturally occurring psychedelic compound found in certain mushrooms. Once ingested, it metabolizes into psilocin, which affects cognition, mood, and perception. Although it remains a Schedule I substance under federal law, psilocybin has reemerged over the past decade as a potential breakthrough therapy for severe mental health conditions. Peer-reviewed research continues to highlight its therapeutic potential in treating major depression, PTSD, substance use disorders, and end-of-life distress. New Mexico's legislation embraces this emerging science by establishing a medical-use program in which licensed clinicians, not dispensaries, administer psilocybin in approved therapeutic settings. The Department of Health is responsible for creating treatment protocols, licensing standards, clinician training, and oversight mechanisms. The Act also establishes both a research fund and a treatment equity fund to expand access and support clinical study. Psychedelic wellness expert Cesar Marin sees the program as a reflection of how far public understanding has evolved. 'We're not talking about the free‑wheeling psychedelic trips of the 1960s anymore,' Marin says. 'We're seeing most states consider or enact some form of psychedelic policy reform, and that momentum helps people feel more comfortable with the intentional, therapeutic use of psilocybin.' Qualifying conditions are narrowly defined to include treatment-resistant depression, PTSD, substance use disorder, and terminal illness. All treatment must occur in controlled environments with preparatory and integration sessions surrounding the administration of psilocybin. Psilocybin and psilocin are removed from the state's list of Schedule I controlled substances when used in accordance with the law, and services provided under the Act are exempt from New Mexico's gross receipts tax. Legal Protections Without Workplace Requirements The Medical Psilocybin Act offers strong protections for individuals operating within its boundaries. Licensed clinicians, producers, and qualified patients cannot be prosecuted under state law, and individuals on probation or awaiting trial may participate in treatment without jeopardizing their legal status. However, the Act stops short of granting any employment-based rights. It does not require employers to accommodate psilocybin use, nor does it prevent adverse action based on lawful participation in the program. That omission is deliberate and significant. While patients may legally participate in psilocybin-assisted therapy under state law, the federal classification of psilocybin as a Schedule I substance remains unchanged. And unlike medical cannabis laws in some states, New Mexico's psilocybin law provides no employment protections, no retaliation standard, and no accommodation framework. Still, employers should not assume the workplace will remain untouched. A New Compliance Challenge for Employers 'New Mexico legalizing medical psilocybin is a huge step toward bringing these treatments out of the shadows and into mainstream medicine,' says Marin. 'When folks see local leaders endorsing these programs, it lowers the fear factor and makes it easier for someone who's curious to explore them.' That shift in perception could soon reach the workplace. Employers may begin receiving accommodation requests from individuals participating in medically supervised psilocybin therapy for conditions like PTSD, treatment-resistant depression, or substance use disorder. And while psilocybin remains a federally controlled substance, the conditions it treats are often considered disabilities under the Americans with Disabilities Act (ADA). That means employers have a legal obligation to engage in the interactive process when an employee discloses a disability and requests accommodation, even if the employee's treatment involves a Schedule I substance like psilocybin. The ADA does not require employers to accommodate federally illegal drug use, but it does require them to consider accommodations related to the underlying condition. Employers are not obligated to tolerate on-the-job impairment or excuse safety violations. Still, if an employee reports off-duty participation in a licensed psilocybin program tied to a recognized condition, a flat denial without further inquiry could invite scrutiny under disability discrimination laws. Testing vs. Impairment: Where Policy Meets Practicality Psilocybin presents unique challenges when it comes to workplace drug testing. Unlike THC or opioids, psilocin, the active compound after ingestion, is not included in most standard employment drug panels. That means employers may be flying blind when it comes to detecting recent psilocybin use unless they specifically request an expanded panel. 'A person can be actively hallucinating due to psilocybin use and still pass a standard workplace drug test,' says Dr. Todd Simo, Chief Medical Officer at HireRight. 'Psilocin, the active compound, doesn't show up in most drug panels unless an employer specifically includes it. That's why training managers to recognize signs of impairment and providing a clear path to escalate reasonable suspicion are more effective strategies. For employers especially concerned, developing a reasonable suspicion panel that includes psilocybin and disclosing it to employees in advance can also help mitigate misuse.' Given that reality, employers may want to prioritize impairment-based enforcement strategies over reliance on traditional drug screening. While testing has its place, especially in post-accident investigations or in regulated industries, training supervisors to recognize signs of real-time impairment and respond consistently under internal policy is likely a more practical approach for most workplaces. Preparing for Disclosure and Dialogue Employers should take this opportunity to review and, where necessary, revise internal policies addressing drug and alcohol use, workplace impairment, and reasonable accommodations. Clarity around off-duty substance use and on-duty safety expectations will be essential. HR teams should also ensure that accommodation request procedures are equipped to handle emerging treatment disclosures, particularly where mental health conditions are involved. Equally important is creating an environment in which employees feel safe discussing mental health. Psilocybin's path to medical legitimacy mirrors, in many ways, the evolution of medical cannabis and broader mental health parity. For employers, staying ahead of these developments will require not only legal awareness but organizational empathy. The Bigger Picture New Mexico's Medical Psilocybin Act signals more than therapeutic access. It reflects a policy evolution, one where lawmakers, not just voters, are beginning to treat psychedelic medicine as a legitimate part of behavioral healthcare. The state's approach shifts the narrative from stigma to structure, putting psilocybin in the hands of trained clinicians operating under medical oversight. And while the law places no new obligations on employers, it surfaces a timely question: what does it mean to support mental health in a world where the frontier of treatment is changing? For employers, that shift invites action. It's time to revisit drug policies, reconsider testing strategies, and refine accommodation practices. As state-level momentum builds around psychedelics, employers don't need to endorse these therapies, but they do need to understand them. Because in the modern workplace, curiosity can be a better compliance strategy than surprise.


UPI
3 days ago
- UPI
Vaccination rates of U.S. kindergartners down, measles cases up
A MMR vaccine information packet is seen at City of Lubbock Health Department in Lubbock, Texas, in March. According to an update from the Texas Department of State Health Services on Friday, there was was an outbreak of measles in the South Plains region of Texas where 146 cases were identified as of late January. New CDC data shows that vaccination rates are down in the United States. Photo by Annie Rice/EPA-EFE July 31 (UPI) -- Vaccination rates among U.S. kindergarten students decreased during the 2024-2025 school year, according to data released Thursday by the U.S. Centers for Disease Control and Prevention and the District of Columbia. Rates ranged from 92.1% for diphtheria, tetanus and pertussis to 92.5% for measles, mumps and rubella. Vaccination rates for polio and varicella dropped in more than half of the states compared to a year prior, the data show. "The number of kindergarteners attending school without documentation of completing the MMR vaccine series was about 286,000 during the 2024-2025 school year," the report said. Overall, the number of kindergartners exempt from one or more vaccines during the 2024-2025 school year reached nearly 138,000, the data showed. The drop in vaccination rates comes amid an uptick in the number of measles cases in the United States. There have been 29 reported outbreaks in 2025, compared with 16 in 2024. Of 1,156 cases reported so far this year, 87% of them have been confirmed, compared to 198 of 285 confirmed cases, or 69%, in 2024.